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Hesam Arabnejad, Elvira Bombino, Dana I. Colpa, Peter A. Jekel, Milos Trajkovic,
Hein J. Wijma, and Dick B. Janssen*[a]
Introduction
The use of biocatalysis in chemistry is an attractive option for
many synthetic processes, especially for preparing fine chemi-
cals and bioactive compounds.[1–7] Although nature provides
an enormous diversity of industrially useful enzymes, they
often must be engineered to meet industrial process require-
ments.[8, 9] In case of pharmaceutical synthesis, of special impor-
tance are chemoselectivity, compatibility with harsh reaction
conditions and product enantiopurity.[1, 10] Consequently, exten-
sive studies have been carried out on controlling and improv-
ing enzyme selectivity by protein engineering, often through
directed evolution,[11] which led to enzymes with improved se-
lectivity in kinetic resolution of enantiomers and better per-
formance in asymmetric transformation of prochiral com-
pounds.[8, 10, 12]
Whereas directed evolution is very successful, it requires
high-throughput screening methods. In case of enzyme enan-
tioselectivity, screening is possible by chiral chromatography or
by the use of quasi enantiomers in NMR or MS[13] but this may
be time-consuming and expensive. Directed evolution be-
comes complicated when no high-throughput expression is
available, such as in case of enzymes that must be produced
in fungi. Several methods have been proposed to overcome
these bottlenecks, such as optimizing strategies for library con-
struction, for example, by focusing mutations in different com-
binations around the active site,[14–16] and by incorporating
structural[9] or phylogenetic information.[17, 18] Another option is
the use of computational tools to design improved en-
zymes.[19–23] Statistical methods have also been used.[24, 25] Bio-
physics-based computational protocols have emerged as pow-
erful platforms for the engineering of thermostable and organ-
ic-solvent compatible enzyme variants.[26–31] Multiple mutations
can be explored simultaneously, allowing for larger jumps in
sequence space than directed evolution and structure-based
rational mutagenesis. Furthermore, in silico screening of
enzyme variants by docking and high-throughput molecular
dynamics simulations makes it possible to predict enzyme
properties and decrease library size for experimental evalua-
tion from thousands to dozens.[32, 33]
In this study, we explore a computational framework (cata-
lytic selectivity by computational design, CASCO)[32] for obtain-
ing enantiocomplementary epoxide hydrolases. This framework
uses the Rosetta scoring function and search algorithm[19, 34] to
generate libraries of primary designs. Next, high-throughput
molecular dynamics (MD) simulations with scoring the frequen-
cy of occurrence of reactive (or near-attack) conformations
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(NACs)[35–37] are used for ranking and to select a small set of
variants that qualify for laboratory testing. The frequency of re-
active poses during MD simulations can explain the selectivity
of computationally designed enzyme variants.[38–40] For that
purpose, generating multiple MD trajectories with independ-
ent assignment of initial atom velocities gives much better
sampling of accessible conformational space than the use of a
single trajectory running over a long simulation time.[41–45] Ac-
cordingly, to enable screening of thousands of Rosetta designs
by MD, CASCO uses 20–80 of such short MD simulations for
scoring conformational stability of designed reactive enzyme–
substrate complexes. The MD step thus examines if the confor-
mation of the enzyme substrate complex, which is partially
constrained during the Rosetta design step (NAC), will be
maintained in short MD runs, or whether that reactive confor-
mation is immediately lost, for example by movement of the
substrate to a non-reactive pose. We used this approach earlier
to predict enantioselectivity in kinetic resolutions catalyzed by
haloalkane dehalogenases.[46]
The potential of this computational approach was illustrated
for limonene epoxide hydrolase (LEH) redesign in a previous
study[32] where we observed that the performance of the best
enzymes in a 37-variant library obtained by the CASCO frame-
work was similar to that of the best variants obtained by
screening approximately 4700 variants generated by the CAST-
ing strategy for directed evolution.[47] Nevertheless, computa-
tional library design for enzyme engineering has serious chal-
lenges, of which reliability of predictions is an important exam-
ple. To further explore the possibilities and limitations of com-
putational redesign, we designed and examined a novel set of
enantioselective limonene epoxide hydrolase (LEH) variants.
LEH catalyzes the hydrolysis of epoxides by activating a
bound water molecule for nucleophilic attack directly on one
of the substrate’s oxirane carbons.[48] The water is positioned
by H-bonds to Asn55 and Tyr53 while Asp132 abstracts a
proton from the water, which enables nucleophilic attack as a
hydroxy ion (Scheme 1). At the same time, Asp101 protonates
the epoxide oxygen, which makes it a better leaving group.
The reaction is concerted.[49] In case of meso-epoxides, the ste-
reochemical outcome is determined by regioselectivity of the
attack and the products are enantiomers. LEH has been exten-
sively used as a model system for exploring the use of directed
evolution strategies to engineer enantioselectivity, and many
variants have been described.[47, 50–55] We previously examined
the use of computational design and screening to improve sta-
bility and control enantioselectivity.[26, 29, 32]
In this work, we investigated three small sets of enantiocom-
plementary epoxide hydrolase variants for converting meso-ep-
oxides (cis-2,3-butene oxide, cyclopentene oxide, and cis-stil-
bene oxide) to their corresponding (R,R)- or (S,S)-diols. For
each target enantiomer, five top-ranked new variants were ex-
perimentally characterized to explore how challenging it is to
position each of the substrates uniquely in the active site. We
also measured kcat and KM values for selected variants. This
showed that the kcat of some variants was higher than of the
thermostable LEH-P variant, from which all mutants were de-
rived. However, the Michaelis constants (KM) were almost
always higher as well, which decreases catalytic efficiency. The
results confirmed the working hypothesis that obtaining
unique binding orientations, reflected in high enantioselectivi-
ty, was easier with the bulkier substrates. Mutants converted
cis-stilbene oxide to diols with an enantiomeric excess (ee) of
>99 %. Small-scale preparative reactions were carried out.
Results
Computational design
The enantioselectivity of limonene epoxide hydrolase is depen-
dent on the regioselectivity of water attack within the active
site. To design epoxide hydrolase variants for enantioselective
conversion of the three substrates (1 a, 2 a, 3 a, Scheme 1), we
performed a series of design calculations for these substrates.
Substrates were docked in the active site and placed in a reac-
tive configuration using restraints. This included a hydrogen
bond between the leaving oxygen and D101, a close distance
between the nucleophilic water and the attacked oxirane
carbon, and close to linear orientation of the nucleophilic
Scheme 1. Conversion of epoxides by limonene epoxide hydrolase. A) regioselective hydrolysis of meso-epoxides examined in this study. B) Catalytic mecha-
nism of LEH, illustrated with proRR hydrolysis of cyclopentene oxide.




water, the oxirane carbon, and the epoxide oxygen. Next, the
Monte Carlo search algorithm of Rosetta was used to optimize
the identity and side chain geometries of amino acids sur-
rounding the active site for either proRR or proSS attack of the
nucleophilic water on the epoxide carbon (Scheme 1). The re-
active geometries were essentially defined as a near attack
conformation (Figure 1 A). The explored sequence space was
created by targeting 11 selected positions around the active
site (Figure 1 B) with randomization to any of the nine hydro-
phobic residues (AFGILMPVW). This way, Rosetta generated
variants forming a low energy complex with the target sub-
strate either in the proRR or proSS orientation, resulting in
thousands of possible proRR and proSS designs per substrate
(Table 1). These sets of primary Rosetta designs represent
mutant libraries enriched in the desired phenotype.
To computationally screen these libraries in an orthogonal
manner by the likelihood of showing the correct regioselectivi-
ty of water attack, we performed molecular dynamics simula-
tions. From MD trajectories, enantioselectivities were predicted
by scoring the fraction of time that the enzyme–substrate
complex is in the same reactive proRR or proSS conformation
used during the Rosetta design step (near-attack conforma-
tions, NACs, Figure 1 A). Instead of a single or a few long MD
simulations, we performed a large number of parallel MD sim-
ulations with independently assigned initial atom velocities
(HTMI-MD), because this gives more extensive conformational
sampling and better agreement with experimental results than
single long simulations.[41–46] For each of the 15 000 Rosetta de-
signs, at least five independently initialized MD runs of 10 ps
were performed (Table 1). Designs that passed initial selection
rounds were subjected to more MD simulations, up to 80 V
10 ps and 5 V 100 ps. NACs were counted on the fly and their
frequency was averaged for each design. The ratio between
averaged NAC frequencies for proRR and proSS attack confor-
mations was used as a predictor for enantioselectivity using
Equation (1). This MD screening of the primary libraries de-
Figure 1. Design of limonene epoxide hydrolases for asymmetric conversion of meso-epoxides. A) NAC criteria used to predict the enantioselectivity of diol
formation from 2,3-butene oxide by MD simulations. The same criteria were used for all three epoxides. Angles and distances are defined as followed: for the
nucleophilic attack angle q1A = 128–1638, q1B = 128–1638 and d1 = 0–3.22 a. For the H-bonds q2-6 = 120–1808 and d2-6 = 0–3.50 a. B) selection of target positions
(cyan) in PDB structure PDB 4R9K. Catalytic residues are shown in yellow, and the substrate in magenta. The targeted amino acid positions are either located
in the peripheral structural elements H1 (M32, L35), H3 (L74), and b3 (M78, I80, V83) which border the proRR side of the substrate binding pocket; or in the
central region, which forms the proSS side of the binding pocket and consists of H4 (F139), b4 (L103), b5 (L114, I116) and b6 (F134). The secondary structure
elements are defined as follows: N-loop (residues 1 to 23), H1 (24 to 35), H2 (40 to 46), H3 (64 to 75), H4 (135 to 143), b1 (52 to 56), b2 (60 to 62), b3 (79 to
91), b4 (94 to 105), b5 (111 to 123) and b6 (126 to 133).
Table 1. Molecular dynamics screening of designed enzyme variants.
CASCO step Criteria No. of designs remaining for substrate
1 a 2 a 3 a
Total Rosetta designs 28 795 33 252 20 714
Rosetta designs with a unique sequence 4125 4732 6232
Designs remaining after MD screening
5 V 10 ps eepred >97 % 711 990 2504
10 V 10 ps eepred >97 % 524 723 2205
20 V 10 ps eepred >97 % 378 587 1631
40 V 10 ps eepred >98 % 170 314 1284
80 V 10 ps eepred >98 % + [NAC]pref >5 % 142 283 978[a]
5 V 100 ps eepred >98 % 63 181 442[b]
Rosetta designs passing all criteria 1.5 % 3.8 % 7.1 %
[a] [NAC]pref indicates the NAC frequency for the preferred product enantiomer. Additional criterion [NAC]pref >10 %. [b] Additional criterion [NAC]pref >5 %.




creased the number of designs by a factor of 15 to 70
(Table 1).
It was noticed during in silico screening by MD that a larger
fraction of the stilbene oxide designs displayed high NAC fre-
quencies and high predicted enantioselectivities than what
was found with cyclopentene and butene oxide designs. As a
result, more stilbene oxide designs survived the final selection
(7.1 %) than designs for cyclopentene oxide 1 a (1.5 %) and
butene oxide 2 a (3.8 %), even though the selection criteria
were set significantly more strict for stilbene oxide than for the
other substrates (Table 1). This suggests a better occupancy of
reactive orientations for stilbene oxide, and more restricted
conformations of the stilbene oxide designs than of the de-
signs with the two smaller substrates, at least during MD simu-
lations.
Visual inspection of the top-ranked designs was carried out
to verify that there were no noticeable structural problems
that would decrease catalytic activity or enantioselectivity. For
every target enantiomer, the variants predicted to have a high
eepred for that product were ranked, those with the highest
[NAC]pref first, and variants were inspected until five variants
were identified for each target enantiomer. It was noticed that
for cyclopentene oxide 1 a and butene oxide 2 a there were
few designs with obvious errors. In 25 inspected designs for
those two substrates there were only five with recognizable
structural errors (one was unusually flexible, three had such a
spacious active site that reorientation of the substrate seemed
likely, and in one mutant there was a new H-bond to the epox-
ide oxygen, Table S1). In contrast, 10 of the 20 inspected var-
iants for stilbene oxide displayed structural problems. Four de-
signs appeared too spacious (Supporting Information) and six
designs had a water positioned such that attack on the unin-
tended carbon atom of the epoxide seemed likely, even
though the NAC analysis did not suggest this.
Experimental characterization
The top five designs for each product enantiomer of the three
substrates were investigated experimentally. Two designs (26A,
45A) were selected twice, both for proRR hydrolysis of cyclo-
pentene oxide 1 a and butene oxide 2 a (Table 2). We also in-
cluded three designs predicted to have proRR selectivity by
molecular dynamics simulation while they were originally de-
signed using Rosetta to have proSS selectivity. The 28 new LEH
variants were constructed in the thermostable LEH-P template
described earlier[56] by sequential rounds of QuikChange muta-
genesis. The use of a thermostable parent enzyme increases
the chance that protein function is maintained upon introduc-
tion of mutations that may be too destabilizing in a mesosta-
ble template and is also reported for directed evolution proto-
cols.[57–59] The LEH template used here (LEH-P, Tm,app = 70 8C,
PDB 4R9K) is not the most stable enzyme from our previous
work, as it lacks the disulfide bonds of the most stable variant
(Tm,app = 85 8C, PDB 4R9L).
[56]
After sequence verification genes were expressed in E. coli
Top10 or 10b for enzyme production. All mutants were well ex-
pressed and could be isolated by His-tag metal affinity chro-
matography. Typical yields were 50–150 mg per liter of culture.
The redesigned LEHs were very stable and could be stored for
over 2 years at @80 8C without loss of activity. Most variants
showed a somewhat lower apparent melting temperature but
more stable variants were also found (Table 2). Overall thermo-
stability was well maintained with an average Tm,app of the re-
designed enzymes of 62.7 8C as compared with 70 8C for the
template LEH-P and 50 8C for the wild-type LEH. Activity assays
were done by mixing purified enzyme with epoxide and meas-
uring diol formation. Of the obtained 28 designs, 26 showed
catalytic activity on the substrate they were designed for. Of
these active variants, 66 % have an activity that is between 10–
164 % of the wild-type activity for their respective substrate.
Chiral analysis of the formed diols revealed that 21 (77 %) of
the designed active variants showed the enantioselectivity pre-
dicted by MD simulations (10 % ee cutoff, Table 2). The cyclo-
pentene oxide (1 a) designs were generated to examine if the
design and selection protocol gave similar results to an earlier
study in which 34 LEH variants were tested for the same sub-
strate.[32] Of the 10 new cyclopentene oxide designs, nine were
active and had the predicted enantioselectivity. The inactive
design was 45A, which was also selected as a design for
butene oxide 2 a, for which it did have a low catalytic activity.
The five proSS designs produced (S,S)-diol 1 b with ee values of
56–85 %, while lower ee values were obtained with proRR de-
signs for (R,R)-1 b. The higher enantioselectivity of proSS de-
signs is in agreement with previous observations.[32]
The butene oxide designs were generated to test the possi-
bility to control regioselectivity of water attack with a very
small prochiral epoxide substrate. All 10 variants were active
and eight of them had the predicted enantioselectivity. As
with cyclopentene oxide, the proSS designs performed better
than the proRR designs, with the best mutant (32A) providing
(S,S)-diol 2 b with 77 % ee The wrong predicted designs had
very low enantioselectivity (ee of 2–6 %). Thus, for both of the
small substrates the MD simulations were an effective tool for
predicting LEH enantioselectivity.
For the largest substrate, stilbene oxide (3 a), six of the eight
active variants showed the predicted enantioselectivity. This in-
cluded two variants (51A, 60A) that were originally designed
using Rosetta to have (S,S)-3 b selectivity but for which the
HTMI-MD screening predicted preferential formation of (R,R)-
diol, which was in agreement with what was observed experi-
mentally. In these cases, MD corrected the Rosetta design pre-
diction. On the other hand, the combination of Rosetta and
MD for design and prediction of enantioselectivity still gave
two mismatches between prediction and experiment in case
of 3 a designs. Of these, variant 52A was exceptional because
it was predicted to give (R,R)-diol 3 b whereas experimentally it
produced (S,S)-diol with high ee (97 %).
Despite the two prediction errors, the results show that
highly enantioselective variants could also be designed com-
putationally for stilbene oxide. The thermostable template
enzyme had 92 % (R,R)-diol selectivity, and four of the eight
active new variants also displayed very high (R,R)-preference
(>91 % ee) whereas two other designed variants displayed
high (S,S)-diol preference (>91 % ee). The more extensive pro-




tein–substrate interactions with a bulky substrate likely result
in more restricted reactive conformations of enzyme–substrate
complexes, accompanied by high product enantioselectivity.
Of the experimentally characterized variants for all three sub-
strates, three have a relatively large (>100 a3) increase in
volume of active site, as calculated from the decreased side
chain volume of introduced amino acids, and indeed these
three variants have low or no catalytic activity (see Supporting
Information). When variants with a predicted increase of the
active site volume of >100 a3 would have been removed from
the libraries, only the primary Rosetta libraries for cis-stilbene
oxide would have shrunken (elimination of 178 of the 442 var-
iants listed in Table 1).
Catalytic properties of the best variants. To examine how
the use of Rosetta for redesign of LEH toward production of a
specific diol enantiomer influences catalytic activity, we exam-
ined the kinetic properties (kcat and KM) of the best mutants
(Table 3). The LEH variants were produced using 1L cultures,
giving again 50–150 mg purified protein per liter of broth,
which was similar to the yield of the parent thermostable
enzyme. Variants RR8 and SS16 were selected earlier as the
best variants from a set of 37 designs for cyclopentene oxide
1 a[32] and were included for comparison (Table 3). The results
showed that 46C and RR8 had catalytic rate constants (kcat) for
cyclopentene oxide that were similar to that of the thermosta-
ble template enzyme LEH-P. Variants 43A and 24A had lower
catalytic constants (2.5- and 7-fold, respectively). Variant SS16
variant displayed an almost 2-fold higher kcat than the template
LEH-P. Thus, catalytic rates were quite well maintained. Howev-
er, in most cases the KM values were higher (8- to 76-fold) for
Table 2. Predicted and observed activities of computationally redesigned limonene epoxide hydrolase variants.
Enzyme Mutations[a] Computational Experimental
NAC % NAC % eepred eeexp Act. Tm,app
proRR proSS [%] [%][b] [%][c] [8C]
cyclopentene oxide (1 a)
LEH-P 14 0.12 U mg@1 70
Designs for
(R,R)-1 b
1A M32L_M78W_I80V_L103F_F139W 5.63 0.000 100 32 2 63.5
43A L74I_L103V_F134Y_F139W 3.86 0.040 98 9 29 67.0
59A M78L_L103V_L114G_I116F_F139I 2.59 0.008 99 6 1 67.0
45A M32L_L74I_L103V_L114W_I116L_F134G_F139W 2.44 0.000 100 –[d] <1 –
46C M32L_L103V_L114A_I116F_F139W 2.08 0.000 100 46 24 57.0
Designs for
(S,S)-1 b
3A M32L_L35W_I80A_I116V_F139W 0.280 36.5 @98 @74 41 –
4C M32L_L35W_I80G_V83I_I116V_F139W 0.208 24.1 @98 @80 55 48.5
24A M32A_M78I_I80F_L103I_I116V_F139L 0.248 23.6 @98 @85 15 68.5
25A M78I_I80F_L103I_I116V_F139L 0.080 19.4 @99 @84 16 73.5
26A L35F_M78F_I80G_I116V_F139W 0.240 19.3 @98 @60 164 45.5
cis-butene oxide (2 a)
LEH-P @2 0.23 U mg@1
Designs for
(R,R)-2 b
47B M32L_L35M_M78I_I80L_V83L_I116M_F134Y 24.1 0.176 99 57 3 56.5
48Ae M32L_L35G_M78L_I80W_L103I_F139L 9.00 0.152 97 24 60 56.0
45A M32L_L74I_L103V_L114W_I116L_F134G_F139W 5.72 0.112 96 18 1 –
49A L103V_L114W_I116L_F134G_F139W 4.14 0.048 98 31 6 59.0
50A M32L_L103V_F134Y_F139M 2.90 0.040 97 @3 15 73.0
Designs for
(S,S)-2 b
30A L74W_I80F_L103I_I116V_F139L 0.496 25.2 @96 @73 11 70.5
31A L35F_M78F_I80A_I116V_F139W 0.320 23.7 @97 @41 100 56.0
32A L35W_L74F_I80G_I116V_F139L 0.080 21.8 @99 @82 15 57.5
33B M32L_I80W_L103I_F139L 0.168 21.0 @98 6 1 78.0
26A L35F_M78F_I80G_I116V_F139W 0.080 20.4 @99 @60 87 45.5
cis-stilbene oxide (3 a)
LEH-P 92 0.35 U mg@1
Designs for
(R,R)-3 b
51Ae M32L_L35G_I80W_L103V_F139W 28.2 0.104 99 91 51 59.5
52A M32L_L35M_M78I_L103I_L114M_I116F 24.9 0.144 99 @97 22 61.0
60Ae M32L_L35G_I80W_L103V_F139L 22.7 0.048 100 >99 52 65.0
61B M32A_I80V_L103V_L114W_I116V_F134G_F139L 22.1 0.136 99 92 3 66.5
38A M32L_M78L_I80V_L103V_F134W_F139L 22.0 0.352 97 >99 11 75.5
Designs for
(S,S)-3 b
62A M32L_I80V_L103V_L114W_I116A_F134G_F139L 0.016 15.5 @100 – <1 71.0
63B M78I_I80L_L103V_L114W_I116V_F134G_F139L 0.240 15.4 @97 40 7 67.0
64C M32A_L103V_L114W_I116A_F134G_F139L 0.152 15.3 @98 – <1 57.5
41B M32L_L35M_L103I_L114M_I116F_F139L 0.072 15.0 @99 @95 21 62.0
65B L74I_M78F_L103V_L114A_I116V_F134W_F139M 0.008 14.7 @100 @28 2 66.0
[a] Mutations at the peripheral (proRR side) of the substrate binding pocket are underlined. Other mutations line the center (proSS side) of the substrate
binding pocket. [b] Positive numbers: (R,R)-diol preference; negative numbers: (S,S)-diol preference. [c] Relative activities expressed in percentage of the ac-
tivity with the template enzyme (indicated). Data from duplicate measurements with the same enzyme batch. [d] –, no activity. [e] Variants designed by Ro-
setta to exhibit (S,S)-product selectivity but predicted by HTMI-MD and found experimentally to produce (R,R)-diol 3 b.




the redesigned LEHs. This might be due to an increase in the
volume of the substrate binding cavity, which grew by 37 a3 in
mutant 46C that had a 76-fold increase in KM for 1 a. The ex-
ception was 24A, which has a 1.4-fold lower KM. In all designs
for 1 a, the specificity constant (kcat/KM) was decreased (Table 3).
The kinetic measurements show that the main cause of the
lower catalytic activities of most designs found during initial
tests (Table 2) is due to a higher KM, not a lower kcat.
The results for the variants designed to convert the other
small substrate, cis-butene oxide 2 a, are similar. For this sub-
strate, we examined 32A, which has the highest enantioselec-
tivity for producing (S,S)-diol and inverted enantioselectivity
relative to the template. It showed an insignificant increase in
kcat, but the KM was much higher, resulting in a drop in kcat/KM
in comparison with the template LEH-P.
The results were different for the variants designed to con-
vert the bulky epoxide stilbene oxide 3 a to (R,R)- or (S,S)-diol.
Here, kcat values were lower than with wild-type, whereas KM
values were better. The observation that kcat values are lowered
in the designs for 3 a whereas NAC percentages during MD
simulations (Table 2) were fine indicates that prediction of reac-
tivities across different substrates using such short MD simula-
tions is troublesome. This is not unexpected, as MD does not
account for energy barriers along reaction coordinates.
The high enantioselectivities obtained for stilbene oxide var-
iants, relative to the designs for the two other substrates, are
likely due a more restricted conformational freedom in case of
the bulky stilbene oxide. The better KM values relative to those
with small substrates might be due to the design procedure
making the active site too spacious for small substrates, pre-
venting a snug fit with good hydrophobic binding interactions.
Stilbene oxide is also more bulky than the natural substrate li-
monene epoxide and the mutations created enough additional
space (ca. 67 a3 for mutant 60A, calculated from decreased
side chain volumes) for tighter binding and a low KM. Conse-
quently, the 3-fold lower kcat of mutant 60A with 3 a was ac-
companied by a 6-fold better KM, leading to an improved cata-
lytic efficiency in 60A. Furthermore, the tight substrate binding
caused the specificity constants (kcat/KM) to be higher for stil-
bene oxide 3 a than for cyclopentene oxide 1 a and cis-2,3-
butene oxide 2 a (Table 3). The improved KM values for 3 a rela-
tive to wild-type were observed with all three tested stilbene
oxide designs.
Preparative scale conversions
The stilbene oxide enantioselectivities of designs 41B and 52A
are higher than reported for other LEH variants tested on this
substrate.[50–52] To examine if these redesigned LEHs could be
used in preparative scale conversions, the conversion of cis-stil-
bene oxide 3 a to the (R,R)- and (S,S)-diols by variants 60A and
41B was examined under different reaction conditions, includ-
ing varying temperatures and cosolvents (Table 4). Cosolvents
were tested because the solubility of the substrates and prod-
ucts in water is low. Even in the presence of 10 % dioxane in
50 mm HEPES, pH 8.0, both cis-stilbene oxide and the diols
were only partially soluble when added at 50 mm. Under these
conditions, the cis-stilbene oxide remained visible as globular
crystals while the (R,R)-diol and the (S,S)-diol formed needles.
The LEH variants 41B and 60A were active in this suspension.
Addition of cosolvents 1,4-dioxane and THF and the presence
of a biphasic system with a layer of ethyl acetate were studied.
No conversion was observed with variant 60A in the biphasic
system with ethyl acetate. Addition of 10 % dioxane gave the
best conversion, yielding up to 78 % diol in 44 h at 30 8C. Re-
markably, adding THF as co-solvent (similar properties as 1,4-
dioxane) gave lower conversion than reaction conditions with-
out cosolvent or with 10 % dioxane. The conversion of cis-stil-
bene oxide by variant 60A was further improved (63 to 80 %)
by increasing the reaction temperature from 30 to 40 8C. The
best conditions (10 % dioxane and 40 8C) were combined and
gave a conversion of 86 and 63 % for variants 60A and 41B, re-
spectively. Increasing the dioxane concentration to 15 % was
beneficial for the proRR variant 60A, yielding a conversion of
98 %, but drastically decreased conversion of 3 a by the proSS
variant 41B. The enantiomeric excess of the stilbene diol prod-
ucts was analyzed by chiral HPLC (Figure S2-S4). For the best
conversions the following results were obtained: >99 % ee for









LEH-P – 1 a 13 (R,R) 0.035:0.004 4.2:0.2 7.9
RR8 (R,R)-1 b 1 a 85 (R,R) 0.039:0.009 189:20 0.20
46C (R,R)-1 b 1 a 34 (R,R) 0.022:0.002 344:17 0.06
43A (S,S)-1 b 1 a 8 (R,R) 0.017:0.005[c] 35:4[c] 0.48
SS16 (S,S)-1 b 1 a @90 (S,S) 0.062:0.001 54:4 1.14
24A (S,S)-1 b 1 a @85 (S,S) 0.005:0.001 3:0.2 1.9
LEH-P – 2 a 24 (R,R) 0.056:0.010 18:1 3.1
32A (S,S)-2 b 2 a @82 (S,S) 0.063:0.002 225:9 0.28
LEH-P – 3 a 92 (R,R) 0.147:0.012 0.37:0.02 406
60A (R,R)-3 b 3 a >99 (R,R) 0.052:0.006 0.06:0.01 890
52A (R,R)-3 b 3 a @89 (S,S) 0.003:0.001 0.16:0.03 19
41B (S,S)-3 b 3 a @94 (S,S) 0.002:0.001 0.19:0.02 10.5
[a] Calculated from multiple data points that is, product enantiomers in different reactions. [b] Averages of duplicate measurements with standard devia-
tion. [c] Single measurement; margins from average coefficient of variation for 1 a data.




(R,R)-stilbene diol (LEH 60A) and 88 % ee for the (S,S)-stilbene
diol (LEH 41B).
Structural origin of enantioselectivity
To provide a structural explanation for the observed mutant
enantioselectivities we inspected the Rosetta designed struc-
tures and the average HTMI-MD structures of selected mutants.
According to these models, the nucleophilic water molecule
stays in virtually the same position (Figure 1, Figure 2). This
agrees with the X-ray structure, in which the catalytic water
has an unusually low B-factor[48] indicating a precise orientation
due to H-bonds from Tyr53, Asn55, and Asp132. The enantiose-
lectivity of the enzyme is therefore determined by the posi-
tioning of substrate relative to this water. In all of the modeled
structures, the positional differences that influence enantiose-
lectivity can globally be described as a sliding motion of the
epoxide carbon atoms in front of the nucleophilic water mole-
cule (Figure 2). Mutations causing the substrate to reside more
toward the center of the dimeric enzyme (i.e. , near b strands
b4, b5, b6, and helix H4, see legend of Figure 1 for residue
numbers) will lead to attack on the (R)-configured carbon of
the epoxide ring, resulting in an (S,S)-diol. Vice versa, proRR
attack will dominate if the substrate is positioned more toward
the peripheral side (i.e. , near b strand b3 and helices H1 and
H3).
In the models of the proSS-selective variants that convert
substrates 1 a and 2 a with high enantioselectivity (ee >75 %),
the dominant substrate orientations are achieved by steric hin-
drance introduced by mutations at the proRR side (e.g. , L35W/
F, L74W/F, M78F, and I80W/F). These mutations will promote
positioning of the substrate more toward the central (proSS)
side. At the same time, space-creating mutations on the proSS
side (I116V and F139L) will further increase the preference for
(S,S)-diol formation. Indeed, designs for substrate 1 a and 2 a
carrying both L35W and I116V gave an (S,S)-diol preference of
>73 % ee (Table 2). Furthermore, also in mutant 32A the steric
hindrance mutations L35F and L74F on the peripheral (proRR)
Table 4. Asymmetric synthesis of stilbene diols by computationally engineered enantiocomplementary epoxide hydrolases.[a]
Temp [8C] Time [h] Conversion [%] ee [%]
Production of (R,R)-diol by LEH 60A
HEPES 50 mm 30 44 63 –[b]
10 % 1,4-dioxane 30 44 78 –
10 % THF 30 44 52 –
At 40 8C 40 44 80 –
10 % 1,4-dioxane 40 24 76 –
10 % 1,4-dioxane 40 48 86 –
15 % 1,4-dioxane 40 48 98 >99 % (R,R)
Production of (S,S)-diol by LEH 41B
HEPES 50 mm 30 44 38 –
10 % 1,4-dioxane 40 24 50 –
10 % 1,4-dioxane 40 48 63 88 % (S,S)
15 % 1,4-dioxane 40 48 18 –
[a] Reaction mixtures (total volume 1 mL) contained 10 mg cis-stilbene oxide (final concentration 50 mm, suspension) and 6.37 mg enzyme (final concentra-
tion 320 mm) in 50 mm HEPES, pH 8.0. [b] –, not determined.
Figure 2. Structural basis of redesigned enantioselectivity. Shown are the
active-site cavities of three proSS- variants (blue shades, names indicated)
and three proRR variants (yellow-orange shades). The variants were designed
for the substrates indicated at the left of each pair of panels. The reacting
water molecules are shown. Hydrogen atoms of substrates are hidden for
clarity. In each panel, both the designed enzyme with its substrate is shown,
as well the position of the same substrate in the opposite design (substrates
in proSS designs in cyan, substrates in proRR designs in yellow). This shows
pronounced differences in substrate positioning and how steric hindrance
steers product enantioselectivity.




side are accompanied by I116V, leading to (S,S)-butanediol for-
mation with the best ee of 77 %.
The origin of the opposite (R,R)-selectivity of variants with
substrates 1 a and 2 a can be explained in a similar way. It is
likely that increased steric hindrance due to mutations on the
central side of the substrate binding cavity (e.g. , mutations
L114W, I116F/M) encourage positioning of the substrate closer
to the peripheral (proRR) side of the binding pocket. This is
visible in mutant 46C for substrate 1 a (e.g. , mutation I116F)
and possibly in 47B for substrate 2 a (e.g. , mutation I116M).
However, such a steric effect is not clear in all predicted proRR
mutant structures, and some designs indeed show low enan-
tioselectivity (e.g. , 45A, 50A). The weakly (R,R)-diol selective
variant 63B contains mutation I116V, creating space on the
central (proSS) side, but it is accompanied by L114W, reducing
that space. The combined effect of such mutations appears dif-
ficult to rationalize in view of effects of side chain interactions
and dynamics.
The mutants designed for stilbene oxide 3 a have high prod-
uct enantioselectivities but the mutations that cause them
appear to not only involve steric effects. The majority of the
3 a designs showed (R,R)-preference, including variant 63B de-
signed for (S,S)-enantioselectivity. Surprisingly, the two most
(S,S)-diol selective mutants for 3 a (52A, 41B) carried mutation
I116F, a mutation that introduces steric hindrance at the cen-
tral side and in case of substrates 1 a and 2 a favors (R,R)-selec-
tivity (see above). The unexpected (S,S)-diol preference might
be due to p–p interactions between the substrate and the
newly introduced aromatic ring of Phe116. The same selectivity
by attraction might hold for one of the best (R,R)-selective mu-
tants: variant 60A (ee >99 %) carries the I80W mutation at the
peripheral (proRR) side and no steric hindrance introducing
mutation on the proSS site. For the other strongly (R,R)-selec-
tive mutant, 38A with ee >99 %, the introduction of steric hin-
drance at the proSS side (F134W) can explain the improvement
in enantioselectivity along the same lines as for substrates 1 a
and 2 a. The wild-type (ee >90 % (R,R)-diol) also has aromatic
functionality with Phe134 at the peripheral (proRR) region.
Thus, it appears possible that enantiomeric preference
with stilbene oxide is partially determined by an influence of
attractive p–p interactions on binding orientations of the sub-
strate.
Instead of a translational shift in the position of substrate,
the stereoselectivity of LEH variants could also be influenced
by rotating the substrate in the binding pocket by 1808 along
an axis formed by the epoxide oxygen and the spot in be-
tween the two epoxide carbon atoms. This would switch the
orientation of the epoxide carbon atoms relative to the nucleo-
philic water. However, such substrate rotations were not ob-
served in any of the models or during MD simulations. Also at-
tempts by us to dock substrates into productive orientations
featuring such a rotation were unsuccessful.
Discussion
Changing enantioselectivity of limonene epoxide hydrolase by
directed evolution has been extensively investigated by Reetz,
Sun and co-workers, focusing on improving directed evolution
strategies including optimizing target positions and positional
diversity in libraries.[47, 50, 52] Such well-optimized directed evolu-
tion protocols still rely on substantial experimental screening
by chiral chromatography, which triggered us to examine if
computational methods could be developed to enrich libraries
and replace most of the laboratory screening by computation-
al screening of protein libraries.[60] In silico screening methods
have been used earlier to design cocaine hydrolyzing enzymes
with improved catalytic efficiency,[61, 62] but also to design libra-
ries of a cytochrome P450 harboring variants with controlled
selectivity,[63] and to increase amidase activity in an esterase.[64]
The results show that design of small sets of mutants with
Rosetta and screening by MD simulations could indeed gener-
ate LEH variants with desired enantioselectivity. Rosetta design
targeted 11 positions at the same time, with a nine-residue di-
versity per position. MD screening was done by multiple ultra-
short simulations with on-the-fly scoring of reactive conforma-
tions and allowed to screen thousands of Rosetta designs. This
CASCO protocol[32] decreased the size of the library required,
and for each substrate only five variants per desired enantio-
mer were used to find mutants with enhanced enantioselectiv-
ity. In case of cyclopentene oxide 1 a, directed evolution[47, 50–52]
and previous computational design[32] gave (S,S)-selective LEH
variants producing the diol with similar ee as found here (60–
95 % ee, Table 2).
A comparison of predicted enantioselectivities as calculated
from NAC percentages (Table 2) shows that there is good over-
all agreement only in qualitative terms, that is, (R,R)- or (S,S)-
diol stereopreference was correctly predicted for 77 % of the
variants using multiple short MD simulations with independent
initialization. On the other hand, within a set of five designs,
experimental activities for individual variants did not correlate
with their computed NAC%, showing that the MD simulations
as performed here do not provide quantitative information on
catalytic rates. Note, however, that rates shown in Table 2 are
strongly influenced by both KM values and do not reflect kcat.
Furthermore, in a broader sense, for each of the three sub-
strates examined, the set of designs that gave the highest
NAC% in MD also showed the highest average activity. Thus,
on average the proRR designs for 3 a were on average more
active than its proSS designs and also gave the highest NAC
percentages for 3 a. For the other two substrates proSS designs
were more active and gave higher NAC%.
In this study, the best enantioselectivities were clearly ob-
tained with stilbene oxide 3 a. Whereas most designs produced
(R,R)-diol 3 b (with ee >99 % for two variants), enantiocomple-
mentary mutants yielding (S,S)-3 b were also found, with a
highest ee of 97 %. With butene oxide 1 a ;[51, 52] the obtained
variants showed high and modest enantioselectivity in the pro-
duction of (R,R)- and (S,S)-diols, respectively. The LEH mutants
found for stilbene oxide could be used to produce enantio-
pure (R,R)-diol and (S,S)-diol at preparative scale, indicating the
potential of this approach to generate a practically useful bio-
catalyst. Ring opening of stilbene oxide was tested earlier
using mutants optimized on cyclopentene oxide and cyclohex-
ene oxide, which resulted in highly (R,R)-selective variants




(with ee 99 %) but only modest (S,S)-selective variants (ee
44 %).[65] The results suggest that the likelihood of obtaining
high enantioselectivity is much better with the bulkier stilbene
oxide than with the smaller substrates, with the two phenyl
rings of stilbene oxide offering more opportunities for steric
hindrance as well as van der Waals and p–p interactions.
Similar to what we found with redesigned aspartases cata-
lyzing asymmetric hydroamination of acrylates,[33] we observed
that the lower activity found with most designs for 1 a and 2 a
as compared with the template (Table 2) was not due to de-
creased kcat, but due to an increase in KM (Table 3). From a prac-
tical point of view, this is less disturbing than the opposite, be-
cause for reasons of process economy preparative-scale appli-
cations must be carried out at high substrate concentrations
anyway. Recently, Sun et al.[65] attributed low activity of LEH
variants obtained by directed evolution to misalignment of the
nucleophilic water, epoxide carbon and epoxide oxygen for an
SN2 reaction, caused by increased flexibility in the active site,
but without reporting kinetic data. This explanation likely does
not hold for the computationally redesigned enzyme studied
by us because such a misalignment would decrease kcat and
probably also KM, which is not what we observe, except for
some stilbene oxide designs (Table 3). Proper alignment of the
nucleophilic water and reacting substrate atoms for SN2 is one
of the constraints in the Rosetta design process and a NAC cri-
terion during MD screening.
Surprisingly, four of the observed enantioselectivities with
stilbene oxide 3 a were opposite to the Rosetta design target
(Table 2). Two of these were corrected in MD simulations. To
understand how these incorrect designs could emerge, we ex-
amined sequences and structures of Rosetta-optimized
enzyme–substrate complexes of all substrates (see above). For
substrates 1 a and 2 a, the observed enantioselectivities could
be explained by the combination of steric hindrance and
space-creating mutations from the peripheral and central side
of the substrate binding pocket, acting together to steer the
substrate in a proRR or proSS binding mode. This did not hold
for several of the mutants designed for stilbene oxide 3 a. For
both variants that are strongly proSS selective for 3 a the only
bulk introducing mutation is I116F, which would be expected
to introduce steric hindrance at the central side of the cavity
and thus stimulate proRR selectivity. Also, for one of the two
most proRR selective variants (60A, ee >99 %) the I80W muta-
tion would be expected to decrease space at the peripheral
side and thereby stimulate proSS selectivity. Thus, it appears
that effects of mutations on bulkiness are poorly related to
stereopreference in case of aromatic substrate 3 a, suggesting
that electronic effects that are not well modeled, such as p–p
interactions, dominate over steric factors in determining sub-
strate positioning or reactivity.
Standard computational design and MD simulations do not
explicitly account for p–p interactions to save computation
time. MD simulations can give more realistic results in cases
where aromatic interactions play a role when the force field is
adapted with an additional noncovalent interaction term.[66]
Whether the main effect of p–p interactions is on binding,
conformational dynamics, or reactivity of bound substrates is
unclear at present. Recently, Zaugg et al.[67] investigated the
origin of enantioselectivity of Aspergillus niger epoxide hydro-
lase in the conversion of the chiral substrate phenyl glycidyl
ether (PGE). Molecular dynamics simulations suggested that
the protein does not differentiate enantiomers based on bind-
ing mode, and free energy calculations did not show signifi-
cant differences between (R)- and (S)-PGE binding either. The
authors suggested that the enantioselectivity is due to kinetic
differences. For such an a/b-hydrolase fold epoxide hydrolase
a computational analysis is more complicated due to the multi-
plicity of reaction pathways and chemical steps. Earlier, Lau
et al.[68] studied murine epoxide hydrolase with (1S,2S)-trans-2-
methylstyrene oxide using ab initio and density functional cal-
culations, and suggested the importance of interactions be-
tween the substrate’s phenyl group and aromatic residues in
the binding pocket. Moreover, Lind and Himo[69] published the
reaction mechanism of a soluble epoxide hydrolase (StEH1)
converting styrene oxide. They proposed coplanarity of the ox-
irane C1-C2 carbons with the substrate’s phenyl substituent,
and p–p interactions between this phenyl group and a histi-
dine and phenylalanine to be important for the stabilization of
the transition state and for the selectivity of the enzyme. Rinal-
di et al.[70] proposed that substrate-dependent LEH regioselec-
tivity is related to reorganization of the active site toward each
ligand. Based on QM/MM calculations, they confirmed that
substrate-specific LEH regioselectivity is due to both conforma-
tional and electronic parameters.
Conclusions
We conclude that computational design and MD simulations
are well able to predict and screen enantioselectivity of LEH
variants in case of small aliphatic substrates. Whereas highly
selective variants for production of aromatic diols can be ob-
tained, prediction accuracy is lower. In view of the effect of in-
teractions involving aromatic groups on epoxide hydrolase
enantioselectivity, rapid scoring methods that more accurately
include effects of p–p interactions appear necessary to further
improve computational screening of LEH variants acting on ar-
omatic substrates.
Experimental Section
Materials. The meso-epoxides and their corresponding diols, oligo-
nucleotides for mutagenesis, organic solvents and glycerol were
purchased from Sigma–Aldrich. Restriction enzymes and PfuUltra
Hotstart PCR Master Mix were obtained from New England Biolabs
and Agilent, respectively. Ni-NTA resin was purchased from GE
Healthcare Life Sciences. SYPRO orange was obtained from Ther-
moFisher Scientific. Complete protease inhibitor cocktail tablets
were bought from Roche. Media components were obtained from
Difco (BD Biosciences).
Computational design. To design LEH variants for production of
highly enantioenriched diols from meso-epoxides the previously
developed CASCO strategy was used with only minor modifica-
tions.[32] The X-ray structure of the wild-type LEH (Protein Databank
1NWW) was used for computational design. Eleven positions
around the active site (M32, L35, L74, M78, I80, V83, L103, L114,




I116, F134 and F139) were selected to mutate simultaneously to
any of the nine hydrophobic residues (AFGILMPVW). Each of the
three substrates was docked in the enzyme active site, either in a
proRR or proSS conformation using Rosetta enzyme design[34, 71]
Catalytically productive binding modes were defined using a con-
straint file as previously.[32] This geometric description of how the
substrate should be bound included the obligation to form H-
bonds between the epoxide oxygen and D101 and between the
nucleophilic water and D132, Y53, and N55. Furthermore, the
water oxygen had to be close (1.8 a) to the attacked carbon atom
while the angle of nucleophilic attack (i.e. , from water oxygen, at-
tacked carbon, and epoxide oxygen) should be close to 1808. An-
other constraint was that the distance between the nucleophilic
water and the non-attacked epoxide carbon atom should be
>3.8 a. To hinder undesired substrate-binding orientations, a
bulky residue (W, F or Y) was introduced at one of the eleven
target positions, as this may reduce binding poses not contributing
to the desired selectivity.[32] Rosetta enzyme design was used to si-
multaneously mutate the remaining ten residues to any of the
nine hydrophobic residues and sequence-conformational space
was searched for substrate-bound structures with low energy and
a catalytically productive binding mode.
High-throughput-multiple independent MD simulations (HTMI-MD)
were used for in silico screening of the generated libraries and to
rank the primary designs with an orthogonal tool (Wijma et al. ,
2014). Independent initialization of multiple trajectories increases
the conformational space sampled by molecular dynamics and de-
creases the computational cost of the screening step relative to a
single long MD run.[46] The reactivity and selectivity of each mutant
were predicted by scoring the fraction of snapshots in which the
enzyme–substrate complex is in a proRR or proSS near-attack con-
formation (NAC). The latter are defined by geometric constraints
(Figure 1), which should be fulfilled for a reaction to become feasi-
ble. The geometric criteria for proRR and proSS attack conforma-
tions were as defined using published quantum mechanical model-
ing.[72] The ratio of proRR and proSS NAC frequencies were consid-
ered to reflect regioselectivity of attack and thus product enantio-
selectivity according to Equation (1),
e:e: ¼ NAC½ A
proRR @ NAC½ AproSSE C
NAC½ AproRR þ NAC½ AproSSð Þ ð1Þ
in which ee is the predicted enantiomeric excess, [NAC]proRR and
[NAC]proSS indicate the fraction of snapshots in which the enzyme–
substrate complex is in a proRR or proSS conformation, respective-
ly. Positive values indicate predicted (R,R)-diol preference, negative
values (S,S) selectivity.
The only modification from the existing procedures are listed in
this paragraph. More design calculations were done than previous-
ly, and also more seeds per MD simulation.[32] For the current
study, approximately 25 thousand design calculations were run per
target substrate (Table 1), which is two times more than previously.
Like earlier,[32] a stepwise scheme to rank the variants was adopted
in which variants were eliminated as soon as they failed a criterion
(Table 1). The selection criteria were based on eepred and [NAC]
values for the preferred enantiomer. The criteria differed per target
substrate and are listed in Table 1. For each designed new variant
20–80 independently started MD simulations of 10 ps were used
(previously maximally 20 MD simulations). For the final variants
also five MD simulations of 100 ps were performed.
Finally, the best ranked mutants were visually inspected. For each
of the targeted product enantiomers, only variants predicted to
have a high enantioselectivity were visually inspected, starting
with those variants that were predicted to have the highest frac-
tions of NACs. The main reasons for elimination of designs were a
too spacious active site cavity or an orientation of the substrate
relative to the water that seemed in disagreement with the pre-
dicted enantioselectivity (Table S1). Only 15 of the 45 inspected de-
signs were eliminated at the stage of visual inspection. Further-
more, no mutations were added at this stage even though this is
common in the field.[73] As a result, the visual inspection only took
a few hours.
Mutagenesis, expression and purification. For the expression of
LEH and variants thereof in E. coli a pBAD based expression vector
was used. This vector contained the gene of the thermostable var-
iant LEH-P with an N-terminal hexa-histidine tag.[56] The computa-
tionally designed variants of LEH-P were constructed by Quik-
Change site-directed mutagenesis using Pfu Ultra Hotstart PCR
Mastermix (Agilent), combining multiple mutations in a single
primer when possible, and omitting sequence verification between
individual mutation steps. PCR reactions, transformations, plating
and final sequencing were done in microtiter plate format.[74] The
obtained plasmids were used to transform chemically competent
E. coli Top10 or E. coli NEB10b cells (Thermo Fischer Scientific). For
expression, cells were grown overnight in 5 mL Luria-Bertani broth
at 37 8C. All cultures were supplemented with 50 mg mL@1 ampicil-
lin. The resulting culture was used to inoculate 500 mL Terrific
Broth medium and incubated at 37 8C and 135 rpm. When an
OD600 of 0.6 was reached, expression was induced by adding
0.04 % (w/v) arabinose and growth was continued at 30 8C and
135 rpm. After 24 h the cells were harvested by centrifugation at
6700 g and 4 8C for 15 min.
For protein isolation, cells were resuspended in 50 mm HEPES
buffer, pH 8, containing 500 mm NaCl (3 mL per gram of cells) and
half of a protease inhibitor cocktail tablet to prevent proteolysis
(Roche Applied Science). After sonication (60 V 10 s with 20 s inter-
vals, Labsonic M), the extract was centrifuged at 35 200 g and 4 8C
for 1 h. The supernatant was collected and the enzyme of interest
was purified by gravity-flow affinity chromatography under native
conditions using Ni-NTA agarose resin (Thermo Fischer Scientific).
The protein concentration of the collected fractions was deter-
mined by a Bradford assay, and selected fractions were desalted by
Econo-Pac 10DG desalting columns (Bio-Rad). The purity of the
prepared enzymes (yield 50–150 mg per L TB medium) was ana-
lyzed by SDS-PAGE. Enzymes were stored at @80 8C until further
use.
Catalytic properties. Chiral chromatography was used to deter-
mine the enantioselective hydrolysis of three meso-epoxides (cis-
2,3-butene oxide, cyclopentene oxide and cis-stilbene oxide) to
chiral diols. In case of cis-2,3-butene oxide and cis-stilbene oxide,
5 mg of purified enzyme was added to 50 mm substrate (virtual
concentration of the suspension) in 50 mm HEPES pH 8 (800 mL
total reaction volume). After incubation of the reaction mixture at
30 8C for 1 h, 500 mL of 5 m NaCl was added and the samples were
extracted three times with 600 mL ethyl acetate. The combined ex-
tracts containing diols were dried by adding anhydrous sodium
sulfate, concentrated under vacuum, and dissolved in 100 mL ethyl
acetate. For cyclopentene oxide, reactions were done in a similar
way after which 250 mg K2CO3 was added to the reaction mixture
followed by extraction for two times by 600 mL of n-butanol. The
combined extract was dried, concentrated under vacuum and re-
suspended in 100 mL n-butanol.




In case of cis-2,3-butene oxide and cyclopentene oxide, chiral anal-
ysis was carried out by injecting 2 mL of the extracts into an Agilent
gas chromatograph equipped with a flame ionization detector and
a Hydrodex b-TBDAc column (Aurora Borealis, initial temperature
40 8C, 10 8C min@1 to 150 8C, hold 20 min). For cis-stilbene oxide and
its diols, samples were analyzed by HPLC on a Luxcellulose-3
column (Phenomenex, Utrecht, the Netherlands) with heptane/2-
propanol (90/10) as the mobile phase (flow rate 1 mL min@1, detec-
tion at 254 nm). Samples from preparative scale reactions with cis-
stilbene oxide and the diols were also analyzed by HPLC on a Chir-
alpak AS-H column (Daicel Corp, Illkirch, France) with n-hexane/2-
propanol (90:10 (v/v) as the mobile phase (1 mL min@1, detection at
254 nm). Enantiomeric excess (ee) values were calculated from con-
centrations of the (R,R)- and (S,S)-product enantiomers.
To obtain steady-state kinetic parameters, initial velocities at differ-
ent substrate concentrations were determined and fitted with the
Michaelis–Menten equation.
Determination of the apparent melting temperature. The Ther-
moFluor assay was used to determine the apparent melting tem-
peratures (Tappm ) of the purified enzyme variants.
[75] This method is
based on monitoring the change in fluorescence of Sypro Orange
dye during the thermal unfolding of a protein. The dye binds to
the unfolded and exposed hydrophobic protein core, increasing its
fluorescence signal. The assays were done as described before.[26]
Synthesis of stilbene diols. Reaction mixtures (total volume 1 mL)
contained 10 mg of cis-stilbene oxide (final concentration 50 mm,
suspension) and 6.37 mg of enzyme (final concentration 320 mm) in
50 mm HEPES, pH 8.0, and were incubated (at 30 or 40 8C,
135 rpm) for 48 h. Substrate and products were extracted three
times by 4 mL ethyl acetate, dried over MgSO4 and filtered. The
solvent was removed by a rotary evaporator. The residue was ana-
lyzed by 1H NMR for conversion and by chiral HPLC to determine
the enantiomeric excess. Chiral HPLC was used as described above.
H.J.W. designed the mutants ; H.A. constructed, isolated, and
characterized the mutants ; H.A. , P.J. , and D.I.C. measured catalyt-
ic activities ; H.J.W., H.A. , and E.B. interpreted the mutants ; D.I.C.
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